Legal Representation
Attorney
John Paul Oleksiuk
USPTO Deadlines
Application History
25 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 18, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 3, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Dec 15, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Dec 15, 2024 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Dec 15, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 13, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jun 11, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 11, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Jun 11, 2024 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Dec 12, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Dec 10, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Dec 10, 2023 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Dec 10, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 20, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Apr 25, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Apr 25, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Apr 5, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Mar 16, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Mar 16, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Mar 16, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Mar 16, 2023 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Mar 16, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Mar 9, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 25, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| May 24, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in diagnosis, prevention, and treatment of diseases in human therapeutics, namely, diseases caused by genetic mutations and diseases and disorders for which gene modification would ameliorate or cure; Gene therapy products, namely, biological preparations based on engineered cells for medical use for the treatment of diseases caused by genetic mutations and of diseases and disorders for which gene modification would ameliorate or cure related to immuno-oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; Pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics, namely, for the diagnosis, prevention, and treatment of diseases caused by genetic mutations and of diseases and disorders for which gene modification would ameliorate or cure; Pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, namely, neurological disorders, Huntington's disease, amyotrophic lateral sclerosis (ALS), front temporal dementia, Alzheimer's, Parkinson's, ataxia, autism, epilepsy, and pain, and also for the prevention and treatment of cardiovascular, peripheral nervous system, endocrine, gastrointestinal, renal, genetic immunological, hepatic, infectious, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, and hematologic diseases and disorders, and cancer
Class 042
Scientific and medical research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic transcriptional regulation, genetic transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering research and development of pharmaceuticals, biological preparations, and therapeutic products and services; Design and development of engineered cells for use in scientific research and in drug discovery and development; Providing medical and scientific research information in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic transcriptional regulation, genetic transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering; Molecular diagnostic services in the nature of genetic testing for medical research purposes
First Use Anywhere:
Oct 1, 2020
First Use in Commerce:
Oct 1, 2020
Class 044
Molecular diagnostic services in the nature of genetic testing for medical purposes; Medical diagnostic testing services in the field of human disease and human medical conditions
Classification
International Classes
005
042
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"